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Mesenteric artery bypass: 
patency determination 
Objective 
Will iam D. McMillan, MD, Walter J, McCarthy, MD,  Michael R. Bresticker, MD, 
Will iam H.  Pearce, MD, Joseph R. Schneider, MD, PhD, John F. Golan, MD,  and 
James S. T. Yao, MD,  PhD, Chicago, Ill. 
Purpose: Many authors have reported extended relief of intestinal ischemia by use of a 
variety of reconstructive techniques, but all have relied on symptomatic follow-up. None 
have objectively measured patency rates. The purpose of this study was to determine the 
primary patency rates of bypass grafts placed for acute and chronic splanchnic 
atherosclerotic o clusive disease with use of objective follow-up with mesenteric duplex 
ultrasound scanning or arteriography. 
Methods: Twenty-five consecutive patients (mean age 61, female/male ratio of 2.7:1) who 
underwent placement of 38 splanchnic bypass grafts (29 saphenous vein grafts, 9 
polytetrafluor0ethy!ene ) (22 retrograde, 16 antegrade) for ischemic symptoms (9 acute 
ischemia: 16 Chronicischemia) between 1984 and 1994 were monitored with either duplex 
scanning (30 grafts) or arteriography. Life-table and log rank analysis were used to 
determine and compare graft patency. 
Results: Three patients (12%, 2 acute ischemia and 1 chronic ischemia) died after 
operation. Six patients (30%) had significant morbidity (4 acute ischemia nd 2 chronic 
ischemia). During follow-up from i to 136 months (mean 35 months), no patient died of 
bowel infarction or required revision for recurrent symptoms. Objective testing revealed 
three graft occlusions. Symptomatic follow-up had a sensitivity of only 33% for graft 
occlusion when compared with objective measurement. The life-table primary patency rate 
was 89% at 72 months. Life-table survival for the same patients was 75% at 36 months. 
Patency rates for antegrade (93% at 36 months) versus retrograde (95% at 36 months) 
0 0 bypass and saphenous vein grafts (95 ~ at 36 months) versus polytetrafluoroethylene (89 
at 36 months) were not significantly different (p = 0.47 and 0.43, respectively). Late 
patency rates of grafts placed for acute ischemia (92% at 36 months) versus chronic 
ischemia (89% at 36 months) were not significantly different (p = 0.77). 
Conclusion: Splanchnic bypass for mesenteric ischemia, with a primary patency rate of 89% 
at 72 months, is an extremely durable form of  revascularization. Long-term patency of 
grafts placed for acute ischemia does not differ significantly from that of bypasses for 
chronic occlusion. Duplex scanning allows standardized objective periodic follow-up of 
splanchnic reconstruction. Objective assessment is critical to accurately measure visceral 
revascularization patency rates. (J VASe SURG 1995;21:729-41.) 
Symptomatic atherosclerotic disease of the mes- 
enteric vessels remains a challenge for the vascular 
surgeon. Although first recognized as a clinical entity 
in 19181 and successfully treated surgically as early as 
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1958, 2debate continues over the optimal operative 
approach, Improvements in surgical technique and 
perioperative intensive care have made long-term 
survival after mesenteric revascularization a reality. A 
variety of  surgical techniques i used today including 
reimplantation, bypass grafting, transaortic endarter- 
ectomy, and patch angioplasty after endarterectomy. 
Over the past decade several reports have demon- 
strated the feasibility and excellent early results that 
are possible with each of these techniques, a~2 
Many of  these same reports examined symptom- 
atic failure rates as the end point in subsets of  patients 
in attempts to identify the  potential benefits of 
particular approaches such as multiple vessel revas- 
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Table I. Symptoms and 
associated conditions 
No. of 
patients Total (%) 
Symptoms 
Pain 25 100 
Weight loss 21 84 
Diarrhea 10 40 
Fear of eating 7 28 
Nausea/vomiting 5 25 
Constipation 3 12 
Associated conditions 
Smoking 22 88 
Hypertension 14 56 
Coronary artery disease 12 48 
Peripheral atherosclerotic 9 36 
disease 
Chronic renal insufficiency 4 16 
Diabetes mellitus 3 12 
cularization,~ ~ supraceliac aortic inf low, 6,13 and trans- 
aortic endarterectomy. 6"12 However, no reports to 
date allow for statistical comparison of objectively 
documented long-term patency rates. Instead, they 
rely on the absence of symptoms as an indicator of 
patency arid objectively assess mesenteric flow only if 
symptoms are present. This has severcly limited 
meaningful comparison of the various techniques. 
Angiography remains the standard and most 
reliable method to document splanchnic patency. 
However, major improvements in mesenteric duplex 
scanning have paralleled those in revascularization 
techniques. Recent double-blind prospective studies 
have validated uplex scanning as a reliable test of 
mesenteric blood flow. ~4,1s Several centers have used 
duplex ultrasonography to document patency of 
bypass grafts after operative treatment of mesenteric 
ischemia.16,17 
The purpose of this study is to objectively 
determine the long-term primary patency rates of 
bypass grafts placed for splanchnic occlusive disease 
documented by duplex ultrasonography or arteriog- 
raphy. 
PATIENTS AND METHODS 
The medical records, including follow-up mesen- 
teric duplex scans, arteriograms, and office records, of 
consecutive patients undergoing bypass grafting 
for symptomatic atherosclerotic eliac, superior 
mesenteric (SMA), or inferior mesenteric arterial 
(IMA) occlusive disease at Northwestern Univer- 
sity/McGaw Medical Center between 1984 and 1994 
were examined. These were identified from a pro- 
spectively acquired atabase Of vascular operations. 
Specifically excluded were all patients undergoing 
mesenteric bypass for celiac artery compression, tho- 
racoabdominal aneurysm, injury, vasculitis, or causes 
other than atheroscterotic disease. Also excluded 
were other methods of revascularization including 
endarterectomy, emb01ectomy, reimplantation, or 
patch angioplasty. 
Twenty-five patients were admitted with symp- 
toms of mesenteric schemia nd eventually under- 
went mesenteric bypass. The patients ranged in age 
from 41 to 78 years with a mean of 61. There were 
more female (n = 17) than male (n = 8) patients, 
and the female/male ratio of 2.7:1 was similar to 
previous reports. 6,~2'18~2~ Nine patients were admitted 
with acute is chemia, and 16 had symptoms of chronic 
intestinal ischemia. The most common presenting 
symptoms, atherosclerotic r sk factors and associated 
diseases, listed in Table I, were similar to those 
reported by previous authors, 11,12,18 
Perioperative patient data are presented in 
Table IL Twenty-five patients required a total of 38 
bypass grafts for a rate of 1.5 bypasses per pa- 
tient. Twenty-nine grafts used saphenous vein (SVG) 
as conduit and nine used polytetrafluoroethylene 
(PTFE). Twenty-two grafts originated below the 
celiac axis and restored flow in a retrograde fashion, 
whereas 16 antegrade grafts originated from the 
supraceliac aorta. Three patients had concurrent 
replacement of the infrarenal aorta, whereas ix had 
simultaneous bowel resection for infarction caused 
by acute ischemia. All patients underwent preferen- 
tial bypass with saphenous vein, particularly those 
undergoing simultaneous intestinal resection. 
Objective vidence of graft patency was obtained 
by mesenteric duplex scanning (n = 30), visceral 
angiography (n = 6) or direct inspection (n = 2). 
Patients undergoing second look procedures (n = 1) 
or autopsy (n = 1) underwent direct inspection. 
Patients tudied before 1989, or within 1 month of 
surgery, underwent angiographic evaluation. The 
remaining patients were evaluated with mesenteric 
duplex scanning. Scans were obtained with a color 
duplex scanner (Ultramark 9; Advanced Technology 
Laboratories, Bothetl, Wash.) by registered vascular 
technicians after an overnight fast with previously 
described techniques. 16 Briefly, 2.5 to 3.5 mHz 
sector transducers with pulsed-wave Doppler sample 
gate of 1.5 mm were used to visualize bypass grafts 
in patients in the supine position with the head of the 
bed elevated to 30 degrees. Doppler waveforms were 
recorded from the aorta and throughout the course of 
the bypass grafts. Graft orientation was compared 
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Table I I .  Patient data 
Age Graft type and bypass 
(yrs.)/sex* Acute/chronic~ (no.Z) Other procedures Reoperat ion  Complicationw 
57/F Chronic 6 mm PTFE Sup None None None 
CcI-SMA (1) 
47/F Acute 6 mm PTFE InAo- None None Kidney failure- 
IMA, SMA (2) resolved 
77/M Chronic RSV Sup Cel- None None None 
Celiac, SMA 
(z) 
72/F Chronic RSV InAo-Cel, None None Prolonged ileus 
SMA (2) 
59/F Acute RSV InAo-Cel, None None None 
SMA (2) 
61/F Chronic RSV InAo-Cel, None None Prolonged ileus 
SMA (2) 
66/F Acute RSV Sup Gel- Small bowel 2nd look c Death: Pneu/MI 
SMA (1) . resection resection 
81/F Acute RSV L Iliac-SMA Small bowel None Home HAL 
(1) resection 
70/M Chronic RSV R Iliac-SMA Small bowel None None 
(1) resection 
66/M Acute RSV Sup Cel- None None None 
Celiac, SMA (2) 
59/F Chronic RSV Sup Cel- None None MI 
SMA (1) 
56/M Chronic 8 mm PTFE In None None None 
Ao-Celiac (1) 
41/F Chronic RSV Sup Cel- None None None 
Celiac, SMA 
(2) 
72/F Chronic 6 mm PTFE L None Redo Ao-Celiac Pneu 
limb ABF- 
SMA, celiac (2) 
63/F Chronic RSV Sup Cel- None None None 
Celiac, SMA 
(2) 
78/F Chronic 6 ram PTFE Ao Repair A_A_A None None 
Tube Graft- 
SMA (1) 
74/M Chronic 6 mm FFFE Ao ABF bypass None MI 
Graft-SMA (1) 
73/F Chronic RSV Sup Cel-Cel, None None None 
SMA (2) 
55/F Acute RSV In Ao-Celiac, R. hemicolectomy 2nd look OK Prolonged ileus 
SMA (2) 
63/F Acute RSV Ao Tube- Repair AAA None CVA 
Celiac, R Iliac- 
SMA (2) 
39/M Chronic RSV Sup Cel- None None None 
Celiac, SMA 
(2) 
62/F Acute RSV R Iliac-SMA Ileocolectomy None Death: CVA/kid- 
( I ) ney failure 
67/M Acute RSV R Iliac-SMA Small bowel None None 
(1) resection 
59/F Chronic RSV R Iliac-SMA None None None 
(1) 
68/F Chronic 6 mm PTFE Sup None None None 
CeI-SMA (1) 
SupCel, Supraceliac aorta; InAo, infrarenal orta; RSV, reversed saphenous vein; Gel, celiac; L, left;R, right;ABF, aortobifemoral;Ao, a rta; 
Pneu, pneumonia; MY, myocardial infarction; HAL, hyperalimcntation~ CVA, cerebrovascular ccident. 
*M:F = 7:18. 
~Acute n = 9; chronic n = 16. 
~Orthograde/retrograde = 18/20; RVG/PTFE = 29/9. 
w rate of 8%; morbidity rate of 30%. 
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Fig. 1. Configuration ofantegrade Supraceliac saphenous vein mesenteric bypass with "piggy 
back" technique. Note single aortic anastomosis and origins.of SMA graft. 
Table III. Life-table patency for mesenteric bypass grafts and cumulative patient survival 
No. of No. of No. withdrawn patent Interval Cumulative Cumulative 
Interval grafts at failed patency patency SE survival SE 
(mo.) risk at start grafts Duration Follow-up Death rate (%) (%) (%) (%) 
0 to 1 38 1 0 0 2 0.97 100.00 0.00 100.00 0.00 
1 to 3 35 0 0 2 i 1.00 97.30 2.70 88.00 6.49 
3 to-6 32 0 0 0 2 1.00 97.30 2.83 88.00 6.65 
6 to 9 30 0 0 1 0 1.00 97.30 2.92 83.80 7.54 
9 to 12 29 0 1 0 2 1.00 97.30 2.97 83.80 7.73 
12 to 24 26 I 3 0 1 0.96 97.30 3.14 79.40 8.49 
24 to 36 21 I 6 0 0 0.94 93.24 5.29 74.70 9.69 
36 to 48 14 0 2 0 0 1.00 88.06 8.I3 74.70 11.87 
48 to 60 12 0 3 0 0 1.00 88.06 8.78 74.70 14.19 
60 to 72 9 0 4 0 0 1.00 88.06 10.14 74.70 16.81 
72 to 84 5 0 2 0 0 1.00 88.06 13.61 74.70 21.69 
84 to 96 3 0 1 0 0 1.00 88.06 17.57 74.70 37.56 
96 to 108 2 0 0 0 0 1.00 88.06 21.51 74.70 37.56 
108 to 120 2 0 0 0 0 1.00 88.06 21.51 74.70 37.56 
120 to 136 2 0 2 0 0 1.00 88.06 21.51 74.70 37.56 
with diagrams of bypass configuration submitted by 
the surgeon to determine accurate placement of 
sample volume~ Waveforms were obtained with a 
measured angle less than 70 degrees to minimize 
artifact in systolic velocity measurements. If no 
waveform could be obtained in a well-visualized 
portion of the bypass graft, the graft was considered 
occluded. 
Life-table patency for splanchnic bypass grafts 
was calculated by use of SVS/ISCVS criteria outlined 
by Rutherford et al. in the JOURNAL OF VASCULAR 
SURGERY. 21 Log-rank testing was undertaken to 
compare patency rates based on acuity (acute isch- 
emia vs chronic ischemia), type of conduit (SVG vs 
PTFE) and graft orientation (a tegrade vs retro- 
grade). 
Surgical technique 
The general techniques for mesenteric artery 
bypass are widely described and available lsewhere. 
However, several variations from the usually de- 
scribed techniques have been used throughout this 
series with success and are thus worth elaborating. 
These include the use of a "piggyback" anastomosis 
for the supraceliac origin of two vein grafts, use of the 
iliac artery for inflow, and placement of a vein graft 
distal anastomosis opposite the usual way to prevent 
kinking on the SMA. 
Supraceliac aortic inflow is an excellent choice for 
reconstruction f the celiac and superior mesenteric 
arterial systems. If possible two bypass grafts are 
recommended for complete revascularization a d 
redundancy in case of a single graft failure. Exposure 
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of the supraceliac aorta and retraction during anas- 
tomosis is facilitated by the use of a self-retaining, 
operating table mounted retractor. Once the suprace- 
liac aorta is dissected, the area available for anasto- 
mosis, even with generous resection of the diaphrag- 
matic crus, is always somewhat limited. After com- 
pleting an end-to-side anastomosis with reverse 
saphenous vein for the aortic-to-celiac bypass, the 
location for a second vein graft inflow from the aorta 
may not be easily obtained. Therefore in this series in 
many cases, the second vein graft was simply 
anastomosed "piggyback" near the origin of the first 
venous hood (Fig. 1). 
The common iliac artery can be effectively used 
for inflow to the SMA. This is particularly useful if 
the infrarenal aorta is severely calcified or in an 
emergency setting when one may not wish, to 
cross-clamp the intrarenal aorta or dissect he su- 
praceliac aorta. The physical pathway of a saphenous 
vein graft from the common iliac to the S/vIA just 
below the ligament of Treitz allows a gentle unkink- 
ing arc despite motion of the bowel with different 
positioning. This bypass configuration can be com- 
pleted with minimal dissection quite quickly in an 
emergency setting (Fig. 2). 
One difficulty with retrograde bypass to the SMA 
is the tendency for bypass graft kinking at the SMA. 
It is difficult o avoid because of the motion from side 
to side and anterior to posterior made by the SMA 
with different body positioning, The tendency not to 
kink may be one of the real advantages of use of 
antegrade perfusion from the supraceliac aorta. As an 
alternative, the distal saphenous veto anastomosis can 
be made to the SMA with the toe and heel lying in 
opposite the usual positions. This configuration 
largely prevents graft kinking with different positions 
of the SMA. Numerous patients in this series 
underwent reconstruction i this manner with no 
known deleterious effect on graft patency (Fig. 2). 
RESULTS 
There were three postoperative deaths. Two 
patients had bowel infarction caused by acute isch- 
cmia and eventually succumbed tomultiorgan failure 
despite patent bypass grafts at second look proce- 
&ires and autopsy. A third patient died on postop- 
erative day 54 ofmultiorgan failure after a supraceliac 
aorta-to-celiac bypass graft acutely thrombosed and 
underwent revision on postoperative day 4. The 
overall early mortality rate of 12% included rates of 
22% for patients with acute ischemia and 6% for 
those undergoing bypass for chronic symptoms. 
Significant morbidity was noted in nearly 30% of 
Celiac 
Superi 
Mesen 
Artery 
SapheM 
Vein_ 
Fig. 2. Configuration f retrograde saphenous vein by- 
pass from iliac artery to SMA with "reversed" distal 
anastomosis. 
patients. Patients undergoing operation for acute 
ischemia had a morbidity rate of 57% including 
stroke (n = 1), prolonged ileus (n = 1), transient 
lddnev failure (n - 1) and malabsorption requiring 
long-term intravenous hyperalimentation (  = 1). 
Only two patients, or 12% of those undergoing 
bypass for chronic mesenteric schemia, had signifi- 
cant postoperative morbidity; both had had a pro- 
longed ileus. 
Twenty-two surviving patients with 34 bypass 
grafts were monitored for 1 to 136 months, with 
a mean follow-up of 35 months, All patients un- 
derwent either duplex scanning or arteriographic 
follow-up so that the patency of every bypass graft 
was determined objectively. Life-table analysis re- 
vealed a primary patency rate of 89% at 72 months 
(Fig. 3, Table III). Two grafts, in addition to the 
clinically apparent early graft failure described pre- 
viously, were found to be occluded in symptom-free 
patients, accounting for the difference between the 
measured patency rate (89%) and apparent symp- 
tomatic patency rate of 97% (1 occluded of 37 total 
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Fig. 3. Life-table patency rates for mesenteric bypass grafts. Solid line indicates cumulative 
patency rates with SE less than 10%. Numbers indicate grafts at risk at beginning of each interval. 
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Fig. 4. Life-table patency rates for antegrade and retrograde orientation. Solid lines indicate 
cumulative patency rate with SE less than 10%. Patency rates were not significantly different 
(p = 0~47). 
grafts). Comparing symptomatic patency to the 
objective measures described (i.e., duplex scanning 
or arteriography), symptomatic evaluation of pa- 
tency had a sensitivity for graft occlusion of only 
33% (one of three occluded grafts). The life-table 
patient survival rate for this group of patients was 
75% at 36 months (Table III). Besides the patient 
with recurrent symptoms on postoperative day 4, 
no patient had development of recurrent symptoms, 
required replacement or revision of mesenteric re- 
vascularization, or died of mesenteric infarction 
during the late follow-up of 1 .to 132 months. 
Life-table patency rates for patients undergoing 
antegrade and retrograde bypasscs were 93% at 36 
months and 95% at 36 months, respectively (Fig. 4, 
Table IV) (p = 0.47). Patency rates were also similar 
for SVG (95% at 36 months) and PTFE (89% at 36 
months) bypasses (Fig. 5, Table V) (p = 0.43). 
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Table IV. Life-table patency for orthograde and retrograde mesenteric bypass 
No. of grafts Number withdrawn patent Interval Cumulative 
Interval at risk No. of patency patency SE 
(mo.) at start failed grafts Duration Follow-Up Death rate (%) (%) 
Orthograde bypass 
0 to 1 18 0 0 0 1 1.00 100.00 0.00 
1 to 3 17 0 0 0 0 1.00 i00.00 0.00 
3 to 6 17 0 0 0 2 1.00 100.00 0.00 
6 to 9 15 0 0 0 0 1.00 100.00 0.00 
9 to 12 15 0 1 0 0 1.00 100.00 0.00 
12 to 24 14 1 1 0 0 0.93 100.00 0.00 
24 to 36 12 0 4 0 0 1.00 92.59 7.27 
36 to 48 8 0 2 0 0 1.00 92.59 8.40 
48 to 60 6 0 2 0 0 1.00 92.59 9.52 
60 to 72 4 0 2 0 0 1.00 92.59 12.60 
72 to 84 2 0 0 0 0 1.00 92.59 17.82 
84 to 96 2 0 0 0 0 1.00 92.59 17.82 
96 to 108 2 0 0 0 0 1.00 92.59 17.82 
108 to 120 2 0 0 0 0 1.00 92.59 17.82 
120 to 132 2 0 2 0 0 1.00 92.59 17.82 
Retrograde bypass 
0 to 1 20 1 0 0 1 0.95 100.00 0.00 
1 to 3 18 0 0 2 1 1.00 94.87 5.06 
3 to 6 15 0 0 0 0 1:00 94.87 5.55 
6 to 9 15 0 0 1 0 1.00 94.87 5.55 
9 to 12 14 0 0 0 2 1.00 94.87 5.74 
12 to 24 12 0 2 0 1 1.00 94.87 6.20 
24 to 36 9 1 2 0 0 0.87 94.87 7.60 
36 to 48 6 0 0 0 0 1.00 82.53 14.08 
48 to 60 6 0 1 0 0 1.00 82.53 14.08 
60 to 72 5 0 2 0 0 1.00 82.53 15.43 
72 to 84 3 0 2 0 0 1.00 82.53 19.91 
84 to 96 1 0 1 0 0 1.00 82.53 34.50 
Finally, there was no difference in long-term patency lack of objective follow-up, because most studies used 
for patients with acute (92% at 36 months) and 
chronic ischemia (88% at 36 months) (Fig. 6, Table 
VI) ~ = 0.77). 
DISCUSSION 
Mesenteric schemia isa rare disease ntity with an 
estimated incidence of one in 100,000 of the general 
symptomatic improvement as the sole indicator of 
graft patency. However, aswas the case in two of our 
patients, symptom-free patients with multiple by- 
passes may have occult graft occlusions. Another 
potential cause for the wide variation in reported 
patency rates is the lack of standardization i
reporting. Many studies report outcomes in selected 
population per year. 22 Manv authors have reported patientsrather than consecutive s ries operated on at 
satisfactory esults with su@cal correction of mes- the same institution. 1~ One group of authors 
enteric ischemia by use of a variety of techniques.312 
However, none of the proponents have objectively 
measured patency rates, making comparisons be- 
tween techniques problematic if not impossible. This 
study documents long-term patency rates for a single 
form of revascularization; namely, mesenteric bypass 
grafting for acute and chronic intestinal ischemia. 
Bypass grafting is arguably the most common 
type of mesenteric revascularization performed to- 
day. A review of previous reports (Table VII) reveals 
a wide variation in reported failure rates (0% to 
40%), with an overall average of 15% at 38 months. 
There are several potential explanations for this 
variability. Some variation may be explained by the 
reported follow-up of patients alive more than 5 years 
after surgery, thereby selecting patients with proven 
long-term patency. I~ Finally differences in surgical 
technique and patient selection all provide potential 
explanations for the wide variation in reported failure 
rates. Our objectively demonstrated primary patency 
rate of  89% at 72 months in consecutive symptom- 
atic patients undergoing splanchnic artery bypass at 
the same institution over the past 10 years should 
eliminate much of the confusion surrounding the 
durability of splanchnic bypass, in view of the 75 % 
3-year survival rate for this same group of patients, 
this patency rate suggests that splanchnic bypass is an 
excellent strategy for mesenteric revascularization. 
TOUI~qM~ or  V~SCUL3_W SUV.G~V.Y 
736 2~lcv] / l i l l an  e t  a l .  May 1995 
o~,,u 
100~ >o-0.r 
q~ 
90- ~O(X~ ~-_-; ~-~-.,.-;.-~ .............. ~ ............ ~'i" ~ i i~  Ni N i~ i ~i i~i i i i i i   ~ ii i i i i i~iii i i i i  ~ 
80~ ................................................................................................................................................................................... 
70  ........................................................................................................................................................................................ 
60 ...................................................................................................................................................................................... 
50 ....................................................................................................................................................................................... 
40 .................................... ~ S:Y "~:---.-~t~nc~.-.s:!~:~-~ 0-~ .............................................. 
,.,.O .... S.V.G. Pateney S.E.>10% 
30 ............................................................................................................................................................................. 
P.T.F.E. Patency S.E.<10% 
20 .................................................................................................................................................................................... 
- ' "O" -  P.T.F.E. Patency S.E,>10% 
10 ......................................................................... ] . ................................................................................................. 
0 
0 1'0 2'0 310 410 510 6'0 710 810 910 160 110 120 130 
Time (Months) 
Fig. 5. Life-table patency rates for SVG and PTFE conduit. Solid lines indicate cumulative 
patency rates with SE less than 10%. Patency rates were not significantly different (p = 0.43). 
,,_.,, 
90 . . . . . . . . . . . . . .  ~, b ..... 8- . . . .  -Be :'z:~'g'-:: "-" ~'-" :-';~8 ......... o- ........ o- ....... 0- 
80- .  ................................................................................................................................................................................... 
70  ........................................................................................................................................................................................ 
60 -  ........................................................................................................................................................................... 
50  ........................................................................................................................................................................................ 
- - -o - -  Acute Isehemia S.E.<10% 
40 .................................................................................................................................................................................... 
---O--.  Acute Ischemia S.E.>10% 
30 ................................................................................................................. : ..................................................... 
----O--- Chronic Isehemia S.E.<10% 
20 ........................................................................................................................................................................................ 
----O--- Chronic Isehemia S.E.>10% 
10 ........................................................................................ ; .. .. .. .. ... .. .. .. ................................................................. 
0 
0 1'0 2'0 3'0 4'0 5'0 6'0 7'0 8'0 9'0 100 110 120 130 
Time (Months) 
Fig. 6. Life-table patency of bypass grafts placed for acute and chronic ischemia. Solid lines 
indicate cumulative patency rates with SE less than 10%. Patency rates were not significantly 
different (p = 0.77). 
Many authors of retrospective r views infer im- 
proved durability with specific forms of revascular- 
ization. 6"s'll'2s Stoney and Schneider 2sand others 6,s 
argue that antegrade flow and prosthetic grafts 25 may 
improve bypass patency, and that transaortic endar- 
terectomy may provide a more durable form of 
revascularization than vein bypass) s However, no 
statistically significant differences among these tech- 
niques have been identified. Within this series we 
detected no difference in objectively measured pa- 
tency rates comparing PTFE and saphenous vein 
conduit or antegrade and retrograde orientation. 
Our inability to demonstrate significant differ- 
ences underscores a problem common in vascular 
surgery. Most of the accepted mesenteric revascular- 
ization strategies provide good initial patency, so that 
numbers of patients must be high to generate the 
statistical power necessary for differentiation be- 
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Table V. Life-table patency rates for SVG and PTFE mesenteric bypass 
No. withdrawn patent 
Interval No. of grafts No. of 
(mo.) at risk at start failed grafts Duration Follow-up Death 
Interval Cumulative 
patency patency SE 
rate (%) (%) 
SVG bypass 
0 to 1 29 0 0 0 2 1.00 100.00 0.00 
1 to 3 27 0 0 2 0 1.00 100.00 0.00 
3 to 6 25 0 0 0 2 1.00 100.00 0.00 
6 to 9 23 0 0 0 0 1.00 100.00 0.00 
9 to 12 23 0 3 0 0 1.00 100.00 0.00 
12 to 24 20 1 0 0 1 0.95 100.00 0.00 
24 to 36 18 1 4 0 0 0.94 94.87 5.06 
36 to 48 13 0 2 0 0 1.00 88.94 8.20 
48 to 60 11 0 4 0 0 1.00 88.94 8.92 
60 to 72 7 0 3 0 0 1.00 88.94 11.18 
72 to 84 4 0 2 0 0 1:00 88.94 14.79 
84 to 96 2 0 0 0 0 1.00 88.94 20.91 
96 to 108 2 0 0 0 0 1.00 88.94 20.91 
108 to 120 2 0 0 0 0 1.00 88.94 20.91 
120 to 132 2 0 2 0 0 1.00 88.94 20.91 
PTFE bypass 
0 to 1 9 1 0 0 0 0.89 100.00 0.00 
1 to 3 8 0 0 0 1 1.00 88.89 10.48 
3 to 6 7 0 0 0 0 1.00 88.89 11.20 
6 to 9 7 0 0 1 0 1,00 88.89 11.20 
9 to 12 6 0 0 0 0 1,00 88.89 12.10 
12 to 24 6 0 3 0 0 1.00 88.89 12.10 
24 to 36 3 0 2 0 0 1.00 88.89 17.11 
36 to 48 1 0 0 0 0 1.00 88.89 29.63 
48 to 60 1 0 0 0 0 1.00 88.89 29.63 
60 to 72 1 0 0 0 0 1.00 88.89 29.63 
72 to 84 1 0 0 0 0 1.00 88.89 29.63 
84 to 96 1 0 1 0 0 1.00 88.89 29.63 
tween techniques. However, because mesenteric 
ischemia is rare, it is unlikely that a single center can 
treat enough patients to demonstrate significant 
differences with a randomized study. Objectively 
documented life-table patency data from several 
institutions are needed for a meaningful metaanalysis 
of patency rates associated with different techniques. 
A major limitation of objective follow-up of 
mesenteric revascularization is the significant mor- 
bidity of angiography and thus its reluctant applica- 
tion in the symptom-free patient. Recently mesen- 
teric duplex scanning technology has evolved so that 
accuracies of greater than 90% are reported. 15
Mesenteric artery scanning became routine at our 
institution after 1989, and subsequent routine quar- 
terly comparisons ofduplex results with angiography 
have documented accuracies exceeding 90% in pa- 
tients undergoing both studies. Every patient in the 
study group returning for late follow-up after 1989 
was successfully studied by our noninvasive labora- 
tory on their initial visit, except those returning 
within 1 month of surgery. Changes including 
residual hematoma, ir surrounding the bypass or 
within PTFE interstices, and limitations caused by 
patient pain or cooperation prevented uplex scan- 
ning within 1 month of surgery. For this reason 
angiography was preferentially used in the two 
patients in our study group examined early in their 
postoperative course because of suspicion of graft 
dysfunction. 
With a combination of angiography and duplex 
scanning, our study demonstrates that symptomatic 
follow-up has limited sensitivity (33%), so that graft 
occlusions are likely to be missed and patency 
overestimated (97% vs 89% in our study). Our 
experience parallels that of other authors who report 
objective follow-up for small percentages of patients 
in their studies (Table VII). Differences between 
symptomatically determined and objectively mea- 
sured patency rates may result from the trend toward 
rnultivessel revascularization. Hollier et al.ll initially 
advocated simukaneous bypass to the celiac, SMA or 
IMA as means to decrease symptomatic recurrence in 
patients undergoing mesenteric revascularization. 
This technique has been successfully used by many 
surgeons and is currently the preferred approach to 
chronic mesenteric schemia t Northwestern. Mul- 
tiple bypasses, by design, increase the number of 
asymptomatic graft occlusions, and in the current 
series both patients with objectively documented 
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Table VI. Life-table patency rates of mesenteric bypass for acute and chronic ischemia 
No. of grafts No. withdrawn patent 
Interval at risk No. of Interval patency 
(mo.) at start failed grafts Duration Follow-up Death rate 
Cumulative 
patency SE 
(%) (%) 
Acute ischemia bypass 
0 to 1 15 0 0 0 2 1.00 
1 to 3 13 0 0 0 0 1.00 
3 to 6 13 0 0 0 0 1.00 
6 to 9 13 0 0 0 0 1.00 
9 to 12 13 0 1 0 0 1.00 
12 to 24 12 1 2 0 1 0.90 
24 to 36 9 0 0 0 0 1.00 
36 to 48 8 0 0 0 0 1.00 
48 to 60 8 0 3 0 0 1.00 
60 to  72 5 0 1 0 0 1.00 
72 to 84 4 0 2 0 0 1.00 
84 to 96 2 0 0 0 0 1.00 
96 to 108 2 0 0 0 0 1.00 
108 to 120 2 0 0 0 0 1.00 
120 to 132 2 0 2 0 0 1.00 
Chronic ischemia bypass 
0 to 1 23 1 0 0 0 0.95 
1 to 3 22 0 0 2 1 1.00 
3 to 6 19 0 0 0 2 1.00 
6 to 9 17 0 0 1 0 1.00 
9 to 12 16 0 0 0 2 1.00 
12 to 24 14 0 1 0 0 0.93 
24 to 36 12 1 6 0 0 1.00 
36 to 48 6 0 2 0 0 1.00 
48 to 60 4 0 0 0 0 1.00 
60 to 72 4 0 3 0 0 1.00 
72 to 84 1 0 0 0 0 1.00 
84 to 96 1 0 1 0 0 1.00 
100.00 0.00 
100.00 0,00 
100.00 0.00 
100.00 0.00 
100.00 0.00 
100,00 0.00 
90.47 9.31 
90.47 9.87 
90.47 9.87 
90.47 12.49 
90.47 13.96 
90.47 19.74 
90.47 19.74 
90.47 19.74 
90.47 19.74 
100.00 0.00 
95.65 4.25 
95.65 4.58 
95.65 4.84 
95.65 4.99 
95.65 5.33 
88.57 8.64 
88.57 12.23 
88.57 14.97 
88.57 14.97 
88.57 29.95 
88.57 29.95 
Table VII. Literature review: mesenteric bypass long-term patency rate (symptomatic follow-up) 
Author 
Graft type Symptomatic failure rates 
Year Patients Grafts Ve in  Synthetic Total (%) Vein (%) Synthetic (%) Mean follow-up (mo.) 
Geelkerken 1~ 1991 6 8 4 4 0 (0) 0 (0) 0 (0) 126 
McFarlane 19 1989 15 24 4 20 4 (17) 4 (100) 0 (0) 38 
Rheudasii 8 1988 34 39 33 6 4 (10) 1 (3) 3 (50) 42 
Beebd s 1987 i0 20 8 12 2 (10) 1 (12) i (8) 43 
Stanton 9 1986 14 16 10 6 0 (0) 0 (0) 0 (0) 50 
Rapp 6 1986 20 27 3 27 1 (4) 1 (33) 0 (0) 53 
Hollier n 1981 56 72 37 35 18 (25) 5 (13) 13 (37) 38 
R0gers 4 1981 12 17 4 13 0 (0) 0 (0) 0 (0) 29 
Zelenock 3~ 1980 23 24 16 8 9 (37.5) 7 (44) 2 (25) 54 
Eldof u 1978 3 3 2 1 1 (33) 1 (50) 0 (0) 8 
Stoney 2s 1977 l l  12 6 6 5 (42) 5 (83) 0 (0) 39 
McCollum ~8 1976 30 42 16 27 3 (7) 1 (6) 2 (7) 1-20 
Hansen 24 1976 __2 2 ~ 0 O (0) O (0) O (0) 6 
Totals 236 306 134 165 47 (15) 26 (19) 21 (13) 38 ~ 
~Weighted average. 
asymptomatic graft occlusion originally had two 
bypass grafts placed. This finding demonstrates the 
utility of multiple level revascularization in decreas- 
ing symptomatic recurrence, as well as the impor- 
tance of objective follow-up in measuring patency 
rates. Thus, in patients with multiple bypasses, 
studies with symptomatic follow-up will overesti- 
mate patency rates and objective measurement be- 
comes crucial for an accurate assessment of the 
durability of mesenteric reconstruction. Mesenteric 
duplex scanning affords a safe, noninvasive objective 
measure of mesenteric bypass patency, represents a 
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Table VIII. Literature review: objective follow-up of mesenteric reconstruction 
Author Total reconstructed Number Tested Occluded or stenotic (%) Symptomatic (%) 
Geelkerken I~ 23 13 2 (16) 0 (0) 
Kieny 17 51 27 7 (26) 3 (11) 
Stanton 9 14 6 0 (0) 0 (0) 
Current study 36 3_66 4 (11) 1 (3) 
Total 124 82 12 (16) 4 (5) 
significant improvement over symptomatic follow- 
up, and allows an accurate stimate of mesenteric 
revascularization durability. 
Many previous reports demonstrate that patients 
with acute ischemia fare less well than those with 
chronic disease, with operative mortality rates ap- 
proaching 60% in some series. 2629 Patients with 
acute ischemia also had a poorer outcome than 
patients with chronic ischemia in our study, with 
mortality rates of 22% and 6%, respectively. The 
22% mortality rate for acute ischemia may reflect 
referral patterns or patient selection. Treatment of 
a more favorable group of patients may improve 
results. Conversely, referral or selection of "all 
comers" undoubtedly adversely affects early mortality 
rates. Of interest, we noted no significant difference 
in the long-term graft patency rates for patients 
undergoing bypass for acute (92% at 36 months) 
versus chronic (88% at 36 months) symptoms. This 
suggests that patients with acute ischemia who 
survive may fare as well as patients with chronic 
ischemia in terms of graft patency. 
Based on the results o f  this study, we conclude 
that splanchnic bypass for mesenteric ischemia is an 
extremely durable form of revascularization, with 
primary patency of 89% at 72 months. Mesenteric 
duplex scanning can provide a safe objective measure 
of mesenteric bypass patency and allow for more 
meaningful analysis of the results of reconstruction. 
Long-term graft patency for patients with acute 
ischemia does not differ significantly from those of 
patients undergoing bypass for chronic symptoms. 
Standardized objective follow-up is necessary to 
resolve the controversy surrounding the optimal 
revascularization technique. 
We thank Donna Blackburn, RN, RVT, and the Blood 
Flow Laboratory staff of Northwestern Memorial Hospital 
for their technical support and assistance. 
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DISCUSSION 
Dr. Bruce Gewertz (Chicago, Ill.). An alternative 
approach to the operative management of these patients is 
retrograde bypass with PTFE or other externally supported 
graft. Dr, McMillan and colleagues point out that the 
backwards orientation of  the SMA anastomosis is critical. 
We also believe that it is important that the graft be placed 
as proximal as possible on the vessel, so that it lies well and 
will not kink. In patients undergoing retrograde bypass, we 
believe that they should undergo critical evaluation of the 
graft before they leave the hospital. 
In contrast to the authors, we perform antegrade 
bypass with its origin at the supraceliac aorta differently. 
We use a small-diameter Dacron graft, although I believe 
that the piggyback technique described here is very useful 
and one that I will consider in the future. We have not had 
difficulty with the lie of the bifurcated graft, as long as there 
is a very short proximal imb to prevent kinking. 
Were angiograms or duplex images routinely obtained 
before discharge? If  so, can you identify any common 
features of the grafts that occluded? Of the patients who 
had asymptomatic graft occlusions, did they uniformly 
have multiple bypass grafts? Or, stated another way, did 
any patient who had a single bypass graft and subsequently 
was found to have an occlusion remain symptom free? 
Finally, in view of the cost, at what intervals hould duplex 
surveillance be carried out on these patients? In view of 
your report that 66% of the patients were symptom free 
after graft occlusion, what should we do if we discover a 
graft occlusion in a symptom-free patient? 
Dr. William D. McMillan. Whether postoperative 
angiograms are routinely obtained is dependent on when 
the bypass was performed. Early in the series, patients 
routinely underwent postoperative angiography before 
leaving the hospital. However, as the surgeons became 
more comfortable with the procedure, fewer patients 
underwent postoperative angiography. Currently, patients 
do not undergo postoperative angiography unless it is 
clinically indicated. 
Every patient with an asymptomatic graft occlusion 
had multiple bypass grafts. The single patient who bad a 
symptomatic occlusion also had multiple bypass grafts. I
cannot comment on whether it is possible to have 
asymptomatic o clusion if only one bypass graft was placed 
because we do not have any patients in our series in that 
category. 
I do not have a definite answer about he approximate 
interval of follow-up. The current policy is extrapolated 
from the lower extremity bypass experience. We monitor 
these patients 6 months after surgery with a duplex 
examination and thereafter at yearly intervals. I f  we were to 
find an asymptomatic occlusion, we would obtain an 
angiogram to better evaluate the patency of the graft in 
question and the possibility ofstenosis in the second bypass 
graft. We would use this information to decide if surgical 
revision was appropriate. Obviously, we hesitate to operate 
on any patient who is symptom free. 
Dr. G. Melville Williams (Baltimore, Md.). I heard a 
very disturbing report from a group in Gainesville about 
11/2 years ago regarding preoperative treatment with 
intravenous hyperalimentation. Many of their patients, 
about a third as I remember, had development of multi- 
system organ failure after aortoceliac SMA bypass, mani- 
fested principally by liver failure. Half of the patients with 
this syndrome died. Despite this, I found that some of my 
own colleagues continue to use preoperative hyperalimen- 
tation because it seems ensible to attempt o build these 
patients up before surgery. Perhaps the ischemic liver 
cannot handle the hyperalimentation. 
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What is your practice in the preoperative management 
of these patients? Have you seen anything similar to this 
syndrome in the postoperanve p riod? 
Dr. McMillan. No patient underwent long-term 
preoperative hyperalimentation. After operation, a fair 
number of patients required hyperalimentation because of 
prolonged ileus. Except for patients who died of multior- 
gan failure, there were no patients who had liver failure. I 
cannot comment on whether the patients who had 
multiorgan failure were undergoing hyperalimentation at 
the time they had development of hepatic insufficiency. 
Dr. Peter Gloviczki (Rochester, Minn.). The mortal- 
it 3" rate of all patients with acute mesenteric arterial 
thrombosis in our experience is about 70%. Could you 
comment on your 22% mortalitv rate and the mortality 
rate of those patients who did not undergo bypass? 
Dr. McMillan. The 22% mortality rate in patients with 
acute ischemia in our series is below rates published in some 
previous reports. The reason for the discrepancy is unclear, 
but a combination of referrral patterns and the possible 
selection bias toward nonoperative management of patients 
with extensive intestine necrosis at the time of initial 
exploration may have contributed. 
Dr. Robert C. Lowell (Wright-Patterson A.F.B., 
Ohio'). You commented on patency with duplex scanning, 
but could you give information concerning the patients in 
whom you detected plaque or other intimal defects that 
perhaps required revision? How well did the duplex 
scanning results correlate to the operative findings? Do you 
routinely perform fasting and postprandial studies because 
they may improve sensitivity? 
Dr. McMillan. We did not identify any stenosis in the 
patients who were studied. We were unable to obtain 
velocity measurements reliably during follow-up duplex 
examination because of difficult3' in assessing the angle of 
interrogation. We did obtain frequency data and attempted 
to use ratios to assess stenosis. We did not routinely 
perform glucose stress tests at the time of evaluation. 
Dr. John W. Hallett, Jr. (Rochester, Minn.). We've 
been trying to correlate the results of postoperative duplex 
scanning with intraoperative flow measurements. It is 
impossible to measure electromagnetic flow in PTFE 
grafts, but have you made intraoperative flow measure- 
ments on the saphenous vein grafts? We have observed that 
most cases of recurrent intestinal angina occur in patients 
with combined celiac and superior mesenteric flow rates of 
less than 1000 m[/min. Do you have any information on 
the flow rates in your group? 
Dr. McMillan. I do not have any specific information, 
only anecdotal reports of extremely high flow rares in 
certain grafts exceeding 1400 ml/min. Only selected 
patients had electromagnetic flow measurements, and no 
patient in the group with graft occlusions had flow 
measured at the time of their initial operation. 
Dr. William Turnipseed (Verona, Wis.~. The main 
focus of this study was surveillance. I have a question about 
your choice of conduit when performing visceral bypass. 
Do you have a preference based on the nature of the case 
(emergency versus elective) with regard to whether you use 
vein or prosthetic graft material? On the basis of the data 
you have presented, showing equivalent patency rates for 
autogenous and nonautogenous grafts, would you now 
change your practice and select one kind of graft over the 
other? 
Dr. McMillan. In our institution, saphenous vein 
would be the graft material of choice in the emergency 
setting because of the possibility of infection resulting from 
gut necrosis. If reasonable diameter saphenous veto is 
available, it is also the conduit of choice for elective bypass. 
The results of our study showed no statistically significant 
difference between aurogenous and prosthetic onduit; 
however, I would caution that the numbers were small. I 
do not believe that the results of this study will signficantly 
change practice patterns at Northwestern Memorial Hos- 
pital with regard to the choice of conduit in the emergency 
setting. 
